Introduction
============

Esophageal cancer (EC) is one of the most aggressive types of cancers. In China, EC is the fourth leading cause of cancer-associated mortality ([@b1-ol-0-0-7984]). In Western countries, Barrett\'s adenocarcinoma is the most common histological type, whereas esophageal squamous cell carcinoma is dominant in East Asia ([@b2-ol-0-0-7984],[@b3-ol-0-0-7984]). Among the currently available treatments, surgical resection is considered to be a potentially curative option for early stage EC. However, owing to the delay of diagnosis, the majority of patients will miss the optimal window for radical surgery. For patients with locally advanced EC, radiotherapy combined with chemotherapy has become an important therapeutic strategy ([@b4-ol-0-0-7984],[@b5-ol-0-0-7984]). However, the prognosis of recurrent or metastatic EC remains poor, despite the development of novel chemotherapies and targeted drugs. Recently the roles of immune checkpoints and immunotherapies have been investigated in several types of malignancies ([@b6-ol-0-0-7984],[@b7-ol-0-0-7984]).

Programmed death-ligand 1 (PD-L1), is a 40-kDa transmembrane protein, and plays a major role in suppressing the immune system. The binding of PD-L1 to its receptor, PD-1, produces inhibitory signals, leading to evasion of the tumor from host monitoring and induction of therapeutic resistance ([@b8-ol-0-0-7984],[@b9-ol-0-0-7984]). PD-L1 has been reported to be highly expressed in various types of cancers and associated with tumor prognosis, such as in liver cancer, head and neck cancers, and lung cancer ([@b10-ol-0-0-7984]--[@b14-ol-0-0-7984]). Furthermore, numerous studies have found that PD-L1 overexpression could be considered a predictive biomarker for immune checkpoint inhibitors ([@b15-ol-0-0-7984],[@b16-ol-0-0-7984]). With regard to EC, although a number of studies have found that PD-L1 is overexpressed ([@b17-ol-0-0-7984],[@b18-ol-0-0-7984]), the predictive ability of PD-L1 remains controversial.

Increasing evidence has suggested that PD-L1 serves an anti-immune role through the regulation of inflammatory cytokines or signaling pathways. For example, the interleukin 6/Janus kinase/signal transducer and activator of transcription 3 (IL-6/JAK/STAT3) signaling pathway have been reported to regulate PD-L1 expression ([@b19-ol-0-0-7984]). The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR), which are considered to reflect a systemic inflammatory response, have been reported to be associated with poor prognosis in various types of cancers ([@b20-ol-0-0-7984]--[@b22-ol-0-0-7984]). However, there is no consensus regarding the significance of these inflammatory parameters in the prognosis of EC. Furthermore, to date, no study has explored the association between PD-L1 and these systemic inflammatory markers in EC.

Based on these observations, a retrospective analysis of data was performed to assess the significance of PD-L1 expression for predicting survival outcomes in Asian patients treated with definitive CRT, and the associations between PD-L1 and inflammatory markers in EC were further investigated to provide novel insights into the development of immunotherapies.

Materials and methods
=====================

### Patient eligibility and tissue specimens

This study was approved by the Department of Radiation Oncology, The First Affiliated Hospital of China Medical University (Shenyang, China), and patients treated between January 2009 and December 2012 were included. A waiver of individual informed consent was granted. In this study, 104 patients were enrolled based on the following selection criteria: i) Confirmed EC by pathological diagnosis; ii) formalin-fixed paraffin-embedded (FFPE) specimens from pathological biopsy available; iii) all patients were treated with radical radiotherapy or definitive CRT initially and did not receive any prior treatments; iv) neutrophil, lymphocyte, platelet and monocyte counts could be obtained from medical records within a week prior to treatment. Upon application of these criteria, patients with inflammation and any malignancy with the exception of EC were excluded. Tumor stages were determined according to the seventh edition of American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) ([@b23-ol-0-0-7984]). In addition, 10 pairs of surgically resected cancer tissues were collected along with adjacent non-cancerous tissues as controls. Patient clinical and pathological information was also collected from medical records. Due to the restrictions of the selected conditions and the lack of necessary information, pretreatment complete blood profiles were only available for 83 (79.8%) patients. Clinical characteristics are shown in [Table I](#tI-ol-0-0-7984){ref-type="table"}. Descriptive data are represented as means and standard deviations. The follow-up was conducted every 3 months for the first 2 years, then once every 6 months via personal interview or by telephone, the deadline was July 2016.

### Treatment

A non-invasive mask was used to immobilize the patient\'s head and neck during treatment. The primary esophageal gross tumor volumes (GTV-nx) together with involved metastatic lymph nodes (GTV-nd) were determined from imaging examinations, barium meal and endoscopic findings. Clinical target volume (CTV) was defined as the GTV plus 3--5 mm to the anterior, posterior, right and left directions and 2.5 cm into the superior and inferior regions. CTV also encompassed a supraclavicular lymphonodus drawing region (in patients with upper or middle EC) or the drainage area of the lymph nodes around the stomach and cardia (in patients with lower EC). A margin of 0.5 cm in all directions was added to the CTV to generate the planning target volume. The organs at risk were delineated, including the spinal cord, lung and heart/pericardium. CT-based treatment planning was performed using a Pinnacle radiation therapy planning system (version 9.0; Philips Medical systems B.V., Eindhoven, The Netherlands). Patients were treated with intensity-modulated radiation therapy or three-dimensional conformal radiotherapy, which was delivered by a PRIMUS™ linear accelerator (Siemens, AG, Munich, Germany) using 6-MV photon beams. The radiotherapy regimens were 2.0 Gy/day, five times weekly, with a total dose of 60 or 66 Gy. In addition, among the 104 patients enrolled, 41 received concurrent chemotherapy with cisplatin (75 mg/m^2^) by intravenous injection (IV) on day 1 and 5-flurouracil (1,000 mg/m^2^) continuous IV on days 1--4; starting on the first day of irradiation and repeated after 21 days, 10 received sequential chemotherapy with four cycles of chemotherapy before radiotherapy, using the same schedule, And 53 patients received radiotherapy alone.

### Immunohistochemical staining (IHC)

FFPE tumor tissues (4-µm thick) were subjected to IHC with a streptavidin-peroxidase (SP) method (Biotin-Streptavidin Immunohistochemistry Kit; cat no. SP-9001; ZSGB-Bio, Beijing, China). The sections were de-waxed in xylene and ethanol. Antigen retrieval was performed by using a pressure cooker to heat tissue sections in Tris-ethylene-diamine tetra-acetic acid buffer (pH 9.0) for \~4 min. Endogenous peroxidase activity was blocked with 0.3% H~2~O~2~ for 20 min followed by washing twice in phosphate-buffered saline (PBS). The sections were mounted on glass slides, pre-incubated with the blocking serum from the kit (liquid A) and incubated at 4°C overnight with a monoclonal anti-PD-L1 antibody at a 1:300 dilution (cat. no. ab205921; Abcam, Cambridge UK) or PBS instead of primary antibodies as a blank control. Subsequently, incubation at 25°C for 10 min with the biotinylated secondary antibody from the kit (liquid B), horseradish peroxidase (25°C, 15 min, liquid C) and 3,3′-diaminobenzidine chromogen (ZSGB-Bio) were performed sequentially. The slides were then counterstained with hematoxylin. Following dehydration with xylene and gradient ethanol (concentrations, 70, 75, 80, 90, 95 and 100%, in turn) the sections were covered with neutral balsam.

### Evaluation of PD-L1 expression

Immunohistochemical slides were observed under low-power magnification (×40) to identify the extent of staining, and immunostaining was further evaluated at high-power magnification (×200). Two independent observers blinded to all of the clinical data assessed PD-L1 expression semi-quantitatively. PD-L1 expression-positive cases were determined by staining intensity and the percentage of positive tumor cells, according to a method described previously ([@b24-ol-0-0-7984]). Staining intensity was scored on a 4-point scale: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining respectively. The proportion of positive cells were scored as follows: 0, 0% stained cells; 1, 1--30% stained cells; 2, 30--60% stained cells; and 3, \>60% stained cells. Two observers discussed controversial cases, and a single consensus score was established by multiplying the scores for intensity and extent of staining. A receiver-operating characteristic (ROC) curve was calculated and the appropriate cut-off value was selected to distinguish between negative and positive cases. A score of ≥2 was considered to represent positive expression of PD-L1.

### Statistical analysis

All statistical analyses were conducted by SPSS 16.0 software. (SPSS, Inc., Chicago, IL, USA) The associations between the clinicopathological factors and PD-L1 expression were explored using a χ^2^ test. The values of NLR, PLR and LMR were compared according to PD-L1 expression status (positive/negative) using a Student\'s t-test. Spearman\'s correlation tests were used to analyze possible associations. Cox proportional hazards models with univariate and multivariate analyses were performed to assess the associations of clinicopathological factors with OS. The OS rates were calculated using the Kaplan-Meier method and were compared using the log-rank test. All tests were two-sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### PD-L1 expression in EC

The clinicopathological characteristics of the 104 patients with EC are presented in [Table I](#tI-ol-0-0-7984){ref-type="table"}. [Fig. 1A](#f1-ol-0-0-7984){ref-type="fig"} indicated that there was no PD-L1 protein staining in normal esophageal epithelium (magnification ×200). In [Fig. 1B](#f1-ol-0-0-7984){ref-type="fig"}, the negative expression in EC was demonstrated (magnification ×200), as shown in [Fig. 1C and D](#f1-ol-0-0-7984){ref-type="fig"}, PD-L1 was overexpressed on the membrane or in the cytoplasm (or both) of EC cells under different magnifications (×100 and ×200, respectively) in some cases, in contrast to normal esophageal epithelial tissues. Of the 104 EC tissues, 39 (37.5%) showed positive PD-L1 staining and focal distribution. No statistically significant differences in clinical parameters were noted between the groups of positive and negative PD-L1 expression ([Table II](#tII-ol-0-0-7984){ref-type="table"}).

### Association between PD-L1 expression and systemic inflammation biomarkers

Among the 83 patients for whom the complete pretreatment blood profiles were available, the mean values of NLR, PLR and LMR were 2.64±1.34, 138.87±64.69 and 4.62±2.30, respectively ([Table I](#tI-ol-0-0-7984){ref-type="table"}). To further investigate the potential correlation of these blood biomarkers with PD-L1 expression in EC tissues, the 83 patients were divided into two groups according to PD-L1 expression level. The distributions of these blood parameters are shown in the box diagrams ([Fig. 2](#f2-ol-0-0-7984){ref-type="fig"}). The only statistically significant association identified was between NLR and PD-L1 expression level (Student\'s t-test, P=0.001); patients in the PD-L1(+) group had lower NLRs than those in the PD-L1(−) group (Spearman correlation, r=−0.308; P=0.005).

### Prognostic significance of clinical factors and PD-L1 expression

On univariate analyses, it was identified that sex (female vs. male, P=0.029), T-classification (T3-4 vs. T1-2, P=0.045), clinical stage (III vs. I--II, P=0.003), concurrent chemotherapy (performed vs. not performed, P=0.028) and PD-L1 expression (positive vs. negative, P=0.012) were statistically significantly associated with OS ([Table III](#tIII-ol-0-0-7984){ref-type="table"}). On subsequent multivariate analyses, sex (female vs. male; HR, 0.449; 95% CI, 0.229--0.880; P=0.02), clinical stage (III vs. I--II; HR, 2.471; 95% CI, 1.171--5.212; P=0.018), concurrent chemotherapy (performed vs. not performed; HR, 0.590; 95% CI, 0.368--0.945; P=0.028) and PD-L1 expression (positive vs. negative; HR, 0.600; 95% CI, 0.372--0.965; P=0.035) were independent prognostic factors for patients with EC treated with radical CRT ([Table III](#tIII-ol-0-0-7984){ref-type="table"}). Survival curves of these prognostic factors are shown in [Fig. 3](#f3-ol-0-0-7984){ref-type="fig"}. The survival curve of PD-L1 demonstrated that patients with positive PD-L1 expression had increased survival times compared with patients with negative PD-L1 expression, and the median OS times were 26 and 11 months, respectively.

Discussion
==========

The present study, investigated PD-L1 expression, the associations between PD-L1 expression and various inflammatory markers, and the prognostic relevance of these factors in patients with EC treated with definitive CRT. In contrast to previous studies ([@b9-ol-0-0-7984],[@b17-ol-0-0-7984]), this present study offered several novel observations that should be considered. The research on PD-L1 expression in EC was limited and controversial ([@b18-ol-0-0-7984],[@b24-ol-0-0-7984],[@b25-ol-0-0-7984]). In the present patient cohort, 37.5% of EC tissue specimens exhibited positive staining. A review of previous studies regarding PD-L1 expression in EC was conducted ([Table IV](#tIV-ol-0-0-7984){ref-type="table"}); the electronic databases PubMed up to September 2016 were systematically searched. The search was performed using the following terms: 'esophageal cancer;' 'programmed death ligand 1;' (or 'PD-L1'), 'prognosis.' In previous studies, the percentage of cases exhibiting positive PD-L1 expression ranged from 18.4--82.8%. Regarding the differences in PD-L1 expression rate, besides differences in the antibodies used, we speculate that differing PD-L1 evaluation criteria may be responsible for the large range. In the majority of studies, PD-L1 expression scores were determined according to the product of the percentage of stained tumor cells and the intensity of staining, and an appropriate cut-off value was selected to distinguish between negative and positive cases. However, in several reports on PD-L1 expression, the criterion for positive staining was 5% of tumor cells showing membrane staining. For instance, a cut-off value of 5% was commonly used in lung cancer, renal cell carcinoma and melanoma ([@b26-ol-0-0-7984]--[@b28-ol-0-0-7984]). We speculate that different tumors may require different evaluation criteria due to tissue specificity. On the other hand, this divergence is from the PD-L1 itself. PD-L1 expression is dynamic, susceptible to the tumor microenvironment and unevenly distributed in tumor tissue. Thus, it is necessary to formulate a unified standard for evaluation and to explore more accurate detection methods in the future.

It is known that there is a complex relationship between inflammation and immunity, which together constitute the tumor microenvironment, and both are associated with invasion and recurrence in cancer patients. NLR, PLR and LMR are considered systemic inflammatory indicators and have been investigated in patients with various types of tumors ([@b29-ol-0-0-7984]--[@b32-ol-0-0-7984]); however, no consensus has been reached on their association with the prognosis of such patients. The present study explored the hypothesis that the blood parameters of NLR, PLR and LMR are associated with PD-L1 expression and OS. However, the results demonstrated no correlations between OS and NLR, PLR or LMR. Further studies utilizing a larger number of patients would be beneficial. Notably, NLR was associated with PD-L1 expression, whereas PLR and LMR were not. To the best of our knowledge, the present study was the first to demonstrate the correlation between PD-L1 and systemic inflammatory markers in EC. Previous studies on the correlation between PD-L1 and NLR, PLR and LMR have only involved hepatocellular carcinoma (HCC). Wang *et al* ([@b33-ol-0-0-7984]) reported that, in hepatitis B-associated HCC, NLR was associated with PD-L1 expression within the center of the tumor, but NLR was not associated with PLR or prognostic nutritional index (PNI). Furthermore, the group with an NLR greater than the median had higher PD-L1 expression ([@b33-ol-0-0-7984]). In contrast to previous experiments, the present study showed that the NLR value was negatively correlated with PD-L1 expression.

Cancer is a systemic disease; therefore, we considered the results that patients in the PD-L1 (+) group had lower NLRs than those in the PD-L1(−) group may be due to the host response to the tumor. It is reported that tumors are able to secrete a multitude of inflammatory factors, such as granulocyte-colony stimulating factor (G-CSF), IL-6, and interferon-γ (IFN-γ), which could induce systemic reactions ([@b34-ol-0-0-7984]), and can affect the generation of blood cells. Furthermore, PD-L1 expression may be increased in response to cytokine exposure (such as G-CSF and IFN-γ) ([@b35-ol-0-0-7984],[@b36-ol-0-0-7984]). Thus, it is possible that the systemic inflammatory markers correlate with PD-L1 expression. In addition, T cells may act as an intermediary between PD-L1 and inflammatory markers. Several studies have suggested PD-L1 expression in human tumor tissue may lead to T cell exhaustion, while the pretreatment NLR level was found to be closely associated with T cell infiltration ([@b37-ol-0-0-7984]). Furthermore, the relationship between inflammation and immunity may change with the different stages of a tumor. Therefore, the mechanisms between PD-L1 and inflammation require further exploration. The aforementioned blood parameters possess the benefit of being easily obtained and low-cost. The relationship between NLR and PD-L1 expression may provide guidance for the development and adjustment of future immunotherapeutic strategies.

Previous studies have investigated the prognostic value of PD-L1 in EC ([Table IV](#tIV-ol-0-0-7984){ref-type="table"}). Numerous reports demonstrated that patients with positive PD-L1 expression had a higher risk of mortality than patients lacking PD-L1 expression. However, in the current study, PD-L1 protein expression was a protective factor in patients treated with definitive CRT, consistent with the reports by Hatogai *et al* ([@b18-ol-0-0-7984]) and Chen *et al* ([@b25-ol-0-0-7984]) in surgical patients with EC. Furthermore, similar findings were reported in melanoma and, nasopharyngeal carcinoma as well as lung cancer ([@b28-ol-0-0-7984],[@b38-ol-0-0-7984],[@b39-ol-0-0-7984]). It is well-established that the balance between cell birth and cell death is important; once this balance is disrupted, tumor progression will occur ([@b40-ol-0-0-7984],[@b41-ol-0-0-7984]). There may be other pathways or receptors associated with PD-L1 that have not yet been identified, which the effect of antitumor was stronger than the effect of PD-L1 leading to the evasion of tumor cells from host monitoring in tumor microenvironment, when PD-L1 is highly expressed. Furthermore, in all of the aforementioned studies, the patients received surgical intervention, whereas only patients who underwent definitive CRT were enrolled in the present study. This discrepancy between the current findings and previous findings may be explained by the different treatment strategies applied, as radiotherapy and chemotherapy may affect the expression of PD-L1 ([@b9-ol-0-0-7984],[@b42-ol-0-0-7984]). Additionally, radiation is able to produce an immunogenic effect in tumors, which may contribute to the host immune response against tumor cells ([@b43-ol-0-0-7984],[@b44-ol-0-0-7984]). Although a number of unanswered questions require further investigation, the current study suggested that the role of PD-L1 in the prognosis of patients treated with definitive CRT had significant value.

There are certain limitations to the current study. First, due to the retrospective nature, as well as the single-center design, certain data regarding immune parameters could not be obtained. Therefore, a prospective and multicenter study will be necessary in the future to confirm these results. In addition, the sample size was small, due to the restrictions of the inclusion and exclusion criteria. Finally, the, potential mechanisms linking PD-L1 expression with NLR, PLR and LMR were not investigated. Animal experiments and a large range of clinical studies will be conducted in due course.

In conclusion, these findings highlight that, in the tumor microenvironment, PD-L1 expression may reflect antitumor immunity and is a useful prognostic marker. The associations between PD-L1 expression and inflammatory markers provide a novel perspective for the further study of the mechanisms of inflammation and immunity. Given the complexity of the tumor microenvironment, a more comprehensive perspective on tumor therapeutic strategies should be formulated in the future.

![PD-L1 expression in EC and normal esophageal epithelium. (A) No PD-L1 staining in normal esophageal epithelium (magnification, ×200). (B) Negative expression of PD-L1 in EC (magnification, ×200). (C) Positive expression of PD-L1 in the cytoplasm and membrane of EC cells (magnification, ×100). (D) Positive expression of PD-L1 in the cytoplasm and membrane of EC cells (magnification, ×200). PD-L1, programmed death ligand 1; EC, esophageal carcinoma.](ol-15-04-4988-g00){#f1-ol-0-0-7984}

![Correlation between PD-L1 and NLR, LMR and PLR. The two groups, divided according to the positive or negative expression of PD-L1, exhibited differences in NLR values (P=0.001, Student\'s t-test), whereas PLR and LMR did not differ significantly between the groups (P=0.448 and P=0.056, respectively). PD-L1, programmed death ligand 1; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR; lymphocyte-monocyte ratio.](ol-15-04-4988-g01){#f2-ol-0-0-7984}

![Kaplan-Meier curves showing differences in overall survival rates according to (A) sex, (B) clinical stage, (C) receipt of concurrent chemoradiation, and (D) PD-L1 expression in patients with esophageal carcinoma. P-values were determined by log-rank test. PD-L1, programmed death ligand 1.](ol-15-04-4988-g02){#f3-ol-0-0-7984}

###### 

General clinical characteristics of the 104 patients.

  Variables                      Value
  ------------------------------ --------------
  Age (years)                    
    ≤65                          53 (51.0)
    \>65                         51 (49.0)
  Sex                            
    Male                         88 (84.6)
    Female                       16 (15.4)
  Pathological type              
    SCC                          99 (95.2)
    Others                       5 (4.8)
  Location                       
    Upper                        29 (27.9)
    Middle                       52 (50.0)
    Lower                        23 (22.1)
  Length (cm)                    
    ≤5                           46 (44.2)
    \>5--7                       26 (25.0)
    \>7                          32 (30.8)
  T-classification               
    T1-2                         14 (13.5)
    T3-4                         90 (86.5)
  N-classification               
    N0                           36 (34.6)
    N1                           63 (60.6)
    N2                           5 (4.8)
  Clinic stage                   
    I                            5 (4.8)
    II                           21 (20.2)
    III                          78 (75.0)
  Radiotherapy dose (Gy)         
    60                           51 (49.0)
    66                           53 (51.0)
  Therapeutic method             
    Radiotherapy alone           53 (51.0)
    Concurrent chemoradiation    41 (39.4)
    Sequential chemoradiation    10 (9.6)
  Neutrophil count (×10^9^/ml)   4.73±1.89
  Lymphocyte count (×109/ml)     2.00±0.71
  Platelet count (×10^9^/ml)     244.58±78.27
  Monocyte count (×109/ml)       0.51±0.25
  NLR                            2.64±1.34
  PLR                            138.87±64.69
  LMR                            4.62±2.30

All values are presented as the number of patients (with %), except for neutrophil, lymphocyte, platelet and monocyte counts, and NLR, PLR and LMR, which are presented as the mean ± standard deviation. SCC, squamous cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-leukocyte ratio; LMR, lymphocyte-to-monocyte ratio.

###### 

Association between PD-L1 expression and clinical parameters.

                            PD-L1 expression, n        
  ------------------- ----- --------------------- ---- -------
  Patients            104   65                    39   
  Age (years)                                          0.447
    ≤65               53    35                    18   
    \>65              51    30                    21   
  Sex                                                  0.575
    Male              88    54                    34   
    Female            16    11                    5    
  Pathological type                                    0.064
    SCC               99    64                    35   
    Others            5     1                     4    
  Location                                             0.417
    Upper             29    21                    8    
    Middle            52    31                    21   
    Lower             23    13                    10   
  Length (cm)                                          0.273
    ≤5                46    25                    21   
    \>5--7            26    17                    9    
    \>7               32    23                    9    
  T-classification                                     0.103
    T1-2              14    6                     8    
    T3-4              90    59                    31   
  N-classification                                     0.966
    N0                36    22                    14   
    N1                63    40                    23   
    N2                5     3                     2    
  Clinical stage                                       0.276
    I                 5     2                     3    
    II                21    11                    10   
    III               78    52                    26   

PD-L1, programmed death ligand 1; SCC, squamous cell carcinoma; T-, tumor; N-, node.

###### 

Univariate and multivariate analyses of risk factors associated with overall survival in patients treated with radical CRT.

                                                          Univariate analysis   Multivariate analysis                                                                               
  --------------------------- ----------- --------------- --------------------- ----------------------- ---------------------------------------------------- ------- -------------- ----------------------------------------------------
  Age (years)                 ≤65         \>65            0.992                 0.974--1.010            0.375                                                --      --             --
  Sex                         Female      Male            0.478                 0.246--0.929            0.029a                                               0.449   0.229--0.880   0.020^[a](#tfn3-ol-0-0-7984){ref-type="table-fn"}^
  Pathological type           SCC         Others          1.824                 0.573--5.804            0.309                                                --      --             --
  Tumor location              Lower       Upper/middle    0.802                 0.465--1.384            0.428                                                --      --             --
  Tumor length (cm)           \>7         ≤5/5--7         1.236                 0.771--1.982            0.379                                                --      --             --
  T-classification            T3-4        T1-2            2.115                 1.015--4.405            0.045a                                               0.833   0.309--2.247   0.718
  N-classification            N+          N0              1.354                 0.852--2.152            0.200                                                --      --             --
  Clinical stage              III         I/II            2.326                 1.341--4.035            0.003^[a](#tfn3-ol-0-0-7984){ref-type="table-fn"}^   2.471   1.171--5.212   0.018a
  Concurrent chemoradiation   Performed   Not performed   0.602                 0.383--0.948            0.028^[a](#tfn3-ol-0-0-7984){ref-type="table-fn"}^   0.590   0.368--0.945   0.028a
  PD-L1 expression            Positive    Negative        0.552                 0.348--0.877            0.012^[a](#tfn3-ol-0-0-7984){ref-type="table-fn"}^   0.600   0.372--0.965   0.035a
  NLR (mean)                  \>2.64      ≤2.64           1.310                 0.796--2.156            0.288                                                --      --             --
  PLR (mean)                  \>138.87    ≤138.87         1.066                 0.650--1.749            0.800                                                --      --             --
  LMR (mean)                  \>4.62      ≤4.62           0.687                 0.420--1.123            0.134                                                --      --             --

Statistically significant (P\<0.05). Only covariates with P\<0.1 in the univariate analysis were considered in the multivariate analysis. HR, hazard ratio; CI, confidence interval; T-, tumor; N-, node; PD-L1, programmed death ligand 1; SCC, squamous cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-leukocyte ratio; LMR, lymphocyte-to-monocyte ratio.

###### 

Summary of studies reporting PD-L1 expression and survival in patients with esophageal cancer (ranked according to publication time).

                                                                                 Classification (no. of patients)                                                                                                                                                                                             
  ---------- ----- ---------- ------------------------------------------- ------ ------------------------------------- --------------------------------------- ------------------- ------------------------------------- ------------------------------------------------------------ ------------ ---------- --------
  Ohigashi   41    qPCR/IHC   ≥1 (qPCR); ≥10% of TCs (IHC)                43.9   T1 (7); T2 (20); T3 (14)              N0 (15); N1 (26)                        M0 (33); M1 (8)     I (7); II (19); III (7); IV(8)        Surgery                                                      Not listed   Negative   \(45\)
  Loos       101   IHC        ≥4                                          73.3   T1 (39); T2 (27); T3 (35)             N0 (52); N1 (44); N3 (5)                M0 (91); M1 (10)    I (46); II (19); III (27); IV(9)      Surgery                                                      Negative     Negative   \(17\)
  Chen       99    IHC        \>0                                         82.8   T1+T2 (35); T3+T4 (64)                N0 (65); N+ (34)                        M0 (93); M1 (6)     I (5); II (57); III (31); IV (6)      Surgery                                                      Not listed   Negative   \(46\)
  Lim        73    IHC        H-score ≥20                                 56.2   Not listed                            N0 (14); N+ (59)                        Not listed          I (4); II (26); III (43)              Neoadjuvant CRT or chemotherapy prior to surgery             None         Negative   \(42\)
  Leng       106   IHC        ≥3                                          46.2   Not listed                            Not listed                              Not listed          I (17); II (61); III (23); IV (5)     Surgery                                                      Not listed   Negative   \(47\)
  Chen       162   IHC        ≥2                                          45     ≤T3 (100); T4 (62)                    N0 (39); N+ (123)                       M0 (94); M1 (68)    Not listed                            Neoadjuvant CRT or definitive CRT                            Not listed   Negative   \(9\)
  Tanaka     180   IHC        ≥4                                          29.4   T1 (37); T2 (31); T3 (94); T4 (18)    N0 (53); N+ (127)                       M0 (132); M1 (48)   I (19); II (53); III (60); IV (48)    Radical resection with or without neoadjuvant chemotherapy   Not listed   Negative   \(24\)
  Chen       536   IHC        5% of TCs with at least moderate staining   41.4   T1 (28); T2 (92); T3 (405); T4 (11)   N0 (222); N1 (170); N3 (107); N4 (37)   Not listed          I (61); II (195); III (273); IV (7)   Surgery                                                      Positive     None       \(25\)
  Hatogai    196   IHC        ≥1% of TCs with membrane staining           18.4   T1 (0); T2 (32); T3 (157); T4 (7)     N0 (51); N1 (59); N3 (63); N4 (24)      M0 (179); M1 (17)   I (7); II (51); III (121); IV (17)    Surgery                                                      Not listed   Positive   \(18\)
  Zhu        133   IHC        \>5% of TCs                                 42.1   T3 (133)                              N0 (133)                                M0 (133)            Not listed                            Surgery                                                      Negative     Negative   \(48\)
  Ito        90    IHC        ≥7                                          18.9   T1+T2 (52); T3+T4 (38)                N0 (45); N+ (45)                        M0 (80); M1 (10)    Not listed                            Surgery                                                      None         Negative   \(49\)

PD-L1, programmed death ligand 1; T, tumor; N, node; M, metastasis; DFS, disease-free survival; OS, overall survival; qPCR, quantitative PCR; IHC, immunohistochemistry; CRT, chemoradiotherapy; AJCC/UICC, American Joint Committee on Cancer/Union for International Cancer Control; TCs, tumor cells.
